Fintel reports that on January 7, 2025, UBS initiated coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Buy recommendation.
Analyst Price Forecast Suggests 96.89% Upside
As of December 23, 2024, the average one-year price target for Tyra Biosciences is $31.62/share. The forecasts range from a low of $29.29 to a high of $34.65. The average price target represents an increase of 96.89% from its latest reported closing price of $16.06 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Tyra Biosciences is 0MM. The projected annual non-GAAP EPS is -1.61.
What is the Fund Sentiment?
There are 242 funds or institutions reporting positions in Tyra Biosciences. This is an increase of 21 owner(s) or 9.50% in the last quarter. Average portfolio weight of all funds dedicated to TYRA is 0.59%, an increase of 0.15%. Total shares owned by institutions increased in the last three months by 2.21% to 48,667K shares. 
The put/call ratio of TYRA is 0.54, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 10,417K shares representing 19.80% ownership of the company. No change in the last quarter.
Boxer Capital holds 6,448K shares representing 12.26% ownership of the company. No change in the last quarter.
Bvf holds 4,661K shares representing 8.86% ownership of the company. No change in the last quarter.
Canaan Partners XI holds 4,410K shares representing 8.38% ownership of the company. No change in the last quarter.
Nextech Invest holds 4,056K shares representing 7.71% ownership of the company. No change in the last quarter.
Tyra Biosciences Background Information
(This description is provided by the company.)
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra's lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
